Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3 -Mutated AML

Alexander E. Perl; Giovanni Martinelli; Jorge E. Cortés; Andreas Neubauer; Ellin Berman; Stefania Paolini; Pau Montesinos; Maria R. Baer; Richard A. Larson; Celalettin Üstün; Francesco Fabbiano; Harry P. Erba; Antonio Di Stasi; Robert K. Stuart; Rebecca L. Olin; Margaret Kasner; Fabio Ciceri; Wen‐Chien Chou; Nikolai A. Podoltsev; Christian Récher; Hisayuki Yokoyama; Naoko Hosono; Sung‐Soo Yoon; Je‐Hwan Lee; Timothy S. Pardee; Amir T. Fathi; Chaofeng Liu; Nahla Hasabou; Xuan Liu; Erkut Bahceci; Mark J. Levis

doi:10.1056/nejmoa1902688

Abstract

Gilteritinib resulted in significantly longer survival and higher percentages of patients with remission than salvage chemotherapy among patients with relapsed or refractory FLT3-mutated AML. (Funded by Astellas Pharma; ADMIRAL ClinicalTrials.gov number, NCT02421939.).

Keywords

MedicineRefractory (planetary science)Hazard ratioChemotherapySurgerySalvage therapyInternal medicineGastroenterologyConfidence intervalBiology

Affiliated Institutions

Related Publications

Durable Remissions with Ivosidenib in IDH1 -Mutated Relapsed or Refractory AML

Courtney D. DiNardo , Eytan M. Stein , Stéphane de Botton +37 more

In patients with advanced IDH1-mutated relapsed or refractory AML, ivosidenib at a dose of 500 mg daily was associated with a low frequency of grade 3 or higher treatment-relate...

2018 New England Journal of Medicine 1336 citations

Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia

Shannon L. Maude , Theodore W. Laetsch , Jochen Buechner +32 more

In this global study of CAR T-cell therapy, a single infusion of tisagenlecleucel provided durable remission with long-term persistence in pediatric and young adult patients wit...

2018 New England Journal of Medicine 5232 citations

OncogenicCSF3RMutations in Chronic Neutrophilic Leukemia and Atypical CML

Julia E. Maxson , Jason Gotlib , Daniel A. Pollyea +16 more

Mutations in CSF3R are common in patients with CNL or atypical CML and represent a potentially useful criterion for diagnosing these neoplasms. (Funded by the Leukemia and Lymph...

2013 New England Journal of Medicine 555 citations

Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing

Li Ding , Timothy J. Ley , David E. Larson +36 more

Most patients with acute myeloid leukaemia (AML) die from progressive disease after relapse, which is associated with clonal evolution at the cytogenetic level. To determine the...

2012 Nature 1971 citations

Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia

Courtney D. DiNardo , Keith W. Pratz , Vinod Pullarkat +13 more

Abstract Older patients with acute myeloid leukemia (AML) respond poorly to standard induction therapy. B-cell lymphoma 2 (BCL-2) overexpression is implicated in survival of AML...

2018 Blood 1764 citations

Publication Info

Year: 2019
Type: article
Volume: 381
Issue: 18
Pages: 1728-1740
Citations: 1122
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3 -Mutated AML

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

1122

OpenAlex

Cite This

APA Style

                            
                                
                                    Alexander E. Perl, 
                                
                                    Giovanni Martinelli, 
                                
                                    Jorge E. Cortés
                                
                                et al.
                            
                            (2019). 
                            Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML. 
                            New England Journal of Medicine
                            , 381
                            (18)
                            , 1728-1740.
                            https://doi.org/10.1056/nejmoa1902688
                        

Identifiers

DOI: 10.1056/nejmoa1902688

Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML